Search

Your search keyword '"Visser, Pieter-Jelle"' showing total 2,259 results

Search Constraints

Start Over You searched for: Author "Visser, Pieter-Jelle" Remove constraint Author: "Visser, Pieter-Jelle"
2,259 results on '"Visser, Pieter-Jelle"'

Search Results

1. MRI-based and metabolomics-based age scores act synergetically for mortality prediction shown by multi-cohort federated learning

2. Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease

3. Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies

4. Amyloid-PET imaging predicts functional decline in clinically normal individuals

6. Outcome measures for Alzheimer's disease: A global inter‐societal Delphi consensus

7. Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease

8. Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles

9. Depressive Symptoms and Plasma Markers of Alzheimer's Disease and Neurodegeneration: A Coordinated Meta-Analysis of 8 Cohort Studies

10. Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease

12. Augmented reality versus standard tests to assess cognition and function in early Alzheimer’s disease

14. Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study

16. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

20. Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum

22. White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study

24. Involvement of the choroid plexus in Alzheimer's disease pathophysiology: A mouse and human proteomic study.

25. Associations between AD polygenic risk scores and global amyloid deposition in the European AMYPAD consortium.

26. Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation

27. Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia

28. Gray matter network properties show distinct associations with CSF p-tau 181 levels and amyloid status in individuals without dementia

29. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease

30. Increased CSF-decorin predicts brain pathological changes driven by Alzheimer’s Aβ amyloidosis

31. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease

34. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer’s disease polygenic risk score

38. Detecting functional decline from normal ageing to dementia: development and validation of a short version of the Amsterdam IADL Questionnaire

39. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia

41. Connecting dementia risk loci to the CSF proteome identifies pathophysiological leads for dementia.

42. Associations Between Glucose Metabolism Measures and Amyloid-β and Tau Load on PET 14 Years Later: Findings From the Framingham Heart Study.

43. CSF cutoffs for MCI due to AD depend on APOEε4 carrier status

44. The Dementias Platform UK (DPUK) Data Portal

45. Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease

46. Plasma Markers of Alzheimer's Disease Pathology, Neuronal Injury, and Astrocytic Activation and MRI Load of Vascular Pathology and Neurodegeneration: The SMART-MR Study

47. Depressive Symptoms and Plasma Markers of Alzheimer's Disease and Neurodegeneration: A Coordinated Meta-Analysis of 8 Cohort Studies

48. Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study

49. Connecting dementia risk loci to the CSF proteome identifies pathophysiological leads for dementia

50. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis

Catalog

Books, media, physical & digital resources